ERC Belgium is to continue to collect clinical trial data for Sitoiganap following its decision this month to pull the EU marketing application for the investigational autologous cell-based immunotherapy for treating recurrent glioma.
ERC Not Giving Up On Glioma Immunotherapy In EU
EMA Concerned Over Biosimilar Eptacog Alfa Manufacturing
ERC Belgium has pledged to collect more data to convince the European Medicines Agency that Sitoiganap merits approval. Meanwhile, UGA Biopharma said it would address the agency’s objections over its biosimilar version of eptacog alfa.
More from Product Reviews
More from Pink Sheet
• By
The forced departure of CBER Director Peter Marks is a milestone event for the agency, as center directors now are likely to be treated as political positions subject to change with each new administration.
• By
The European Medicines Agency’s latest move towards a more streamlined process for biosimilar registration in Europe was the hottest topic at last week’s annual biosimilars conference held by Medicines for Europe in Amsterdam.
• By
Eli Lilly is seeking an injunction barring a weight loss clinic from dispensing modified versions of its GLP-1 products.